RPL17 and neoplasm: Thus, anti-PD-1 mAb exerts potent effects on the quality of antigen-specific CD8+ T cell activation in the tumor-draining lymph node, promoting a blastic phenotype, increasing clonal expansion, and enhancing functional capacity.